Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 19/20 | 0.43 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CCNH | P51946 | 1/20 | 0.33 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692038 | 0.92 | KRAS (0.37) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL22709123 | 0.89 | KRAS (0.43) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL29423729 | 0.89 | KRAS (0.43) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL22692121 | 0.82 | KRAS (0.65) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL22709111 | 0.82 | KRAS (0.38) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL29423739 | 0.82 | KRAS (0.38) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL23668817 | 0.81 | KRAS (0.46) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL22692114 | 0.80 | KRAS (0.38) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL22692126 | 0.80 | KRAS (0.38) | KRASVHLCDK7CCNHMNAT1 | |
| SCHEMBL22692111 | 0.80 | KRAS (0.38) | KRASVHLCDK7CCNHMNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227738-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-21 | — | — | US | disclosed |
| WO-2022115439-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972978-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020236940-A1 | KRAS G12C INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227738-A1 | KRAS G12C INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885VHL 5/4885CDK7 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.